FDA Must Stop Online Compounders Before Patients Get Hurt

  • by: Peter Pitts |
  • 10/03/2025
FDA Must Stop Online Compounders Before Patients Get Hurt 

Online pharmacies are exploiting patients with knock-off GLP-1 drugs that are untested, unsafe, and illegal. These compounded products are being marketed as containing the “same active ingredient as Ozempic or Wegovy” or as including “clinically proven ingredients”—claims that are outright false. Yet, patients are being misled into believing these drugs are safe and effective. 
 
A January 2025 study found that many websites selling compounded GLP-1s fail to disclose that these products are not FDA-approved, with some even falsely labeling them as “generics.” Many of these drugs are made from active pharmaceutical ingredients sourced from illegal foreign suppliers—primarily in China—posing a serious, avoidable threat to patient safety. 
 
The FDA’s recent warning letters are a step in the right direction, but they barely scratch the surface. Mass compounding of GLP-1s is out of control, and patients are paying the price while mass compounders profit. The FDA already has the authority to act and must follow through with aggressive enforcement: requiring compounders that operate like manufacturers to register as such, cracking down on telehealth schemes disguised as “personalization,” and penalizing repeat offenders. 
 
Patients deserve to know that when the FDA acts, it acts decisively. Until enforcement is consistent and visible, unscrupulous compounders will continue exploiting regulatory weaknesses, putting profits ahead of patient safety, and endangering lives. 

For more on the threat compounded GLP-1s pose to patient safety, see CMPI’s report
 
CMPI

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog